Maralixibat chloride

MARALIXIBAT CHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated in alagille syndrome and pruritus and has 2 investigational indications. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lopixibat chloride and Livmarli. Its PubChem CID is 9831642.

CAS No 228113-66-4
Molecular Formula C40H56ClN3O4S
Molecular Weight 710.40 g/mol
Synonyms (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1λ6-benzothiepin-4-ol chloride

Frequently Asked Questions